Alzamend Neuro, Inc. files regulatory reports that document its status as a Nasdaq-listed clinical-stage biopharmaceutical company and emerging growth company. Recent disclosures cover common stock registered on The Nasdaq Capital Market, annual meeting and proxy matters, stockholder voting results, and board and governance records.
The company's filings also describe capital-structure activity, including at-the-market offering documents, unregistered common stock issuances tied to convertible preferred stock, elimination of Series B and Series C preferred stock designations, and Nasdaq continued-listing compliance matters. These records frame ALZN's financing, governance and public-company reporting obligations around its neurodegenerative and psychiatric-disorder development programs.
Alzamend Neuro, Inc. holders led by Milton C. Ault III report combined beneficial ownership of 166,909 shares, representing approximately 4.4% of the company's 3,739,861 outstanding shares as of October 7, 2025. The filing aggregates direct holdings, shares underlying Series B convertible preferred stock and exercisable warrants, and stock options across related entities including Hyperscale Data, Ault Lending, Ault Life Sciences and others.
The statement breaks out voting and dispositive power: Mr. Ault holds 1,843 shares directly and shared voting power over 165,066 shares; Hyperscale Data and Ault Lending each report beneficial ownership of roughly 153,937 and 153,925 shares respectively (about 4.0%). Purchase prices for several block holdings are disclosed in aggregate dollar amounts, and no transactions in the past 60 days are reported except as listed in an exhibit.
Alzamend Neuro (ALZN) filed Amendment No. 10 to Schedule 13D, updating beneficial ownership by Milton C. Ault III and affiliated entities. The filing is based on 3,539,861 shares outstanding as of October 2, 2025.
Mr. Ault may be deemed to beneficially own 306,321 shares, or approximately 8.0% of the class, including direct holdings and shares attributable through affiliates. Hyperscale Data, Inc. reports 293,349 shares (approximately 7.7%), and Ault Lending, LLC reports 293,337 shares (approximately 7.7%). These positions include 261,743 shares underlying Series B Convertible Preferred Stock and 23,334 shares underlying currently exercisable warrants held by Ault Lending, plus smaller direct common holdings across affiliates.
The filing details voting and dispositive powers across entities and notes that no transactions in the past 60 days occurred other than those listed in an exhibit.
Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in early October 2025. On 10/01/2025 he converted Series B convertible preferred shares into 100,000 shares of common stock at a conversion price of $2.32. On 10/01–10/03/2025 he sold common shares in open-market transactions: 36,777 shares on 10/01 at a VWAP of $2.3487, 20,686 shares on 10/02 at $2.394, and 65,903 shares on 10/03 at a VWAP of $2.4413, totaling 123,366 shares sold.
The Form 4 lists changing beneficial ownership figures tied to Ault-controlled entities: following the conversion Ault Lending is reported with 131,626 shares beneficially owned, which moved to 94,849, then 74,163, and then 8,260 after the sales. Additional holdings are shown for Ault Life Sciences, Inc. (11,068) and Ault Life Sciences Fund, LLC (61), with voting and investment power described in the filing.
Alzamend Neuro, Inc. (ALZN) Schedule 13D/A discloses that Milton C. Ault, III and affiliated entities beneficially own a combined 429,687 common shares, representing approximately 11.2% of the 3,439,861 shares outstanding reported by the issuer. That total includes direct holdings, stock options, warrants and shares underlying Series B convertible preferred stock held across Hyperscale Data, Ault Lending, Ault Life Sciences and related entities.
The filing breaks out ownership and voting/dispositive power: Mr. Ault directly holds 1,843 shares and shares control of 427,844 shares; Hyperscale Data and Ault Lending each report approximately 10.9% beneficial ownership. The filing states sources of funds for purchases (working capital or personal funds) and lists aggregate purchase prices for several holdings and instruments. No transactions in the past 60 days are reported except as set forth in Exhibit 1.
Milton C. Ault III, identified as a director and a 10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple sales of the company’s common stock in late September 2025. The filings show sales on 09/26/2025 of 37,738 shares at $2.3145, on 09/29/2025 of 38,324 shares at $2.309, and on 09/30/2025 of 3,566 shares at $2.3334. After those transactions, beneficial ownership reported for the related entities was 73,516 shares (indirect) by Ault Lending, LLC, 35,192 shares (indirect) by Ault Lending, LLC, and 31,626 shares (indirect) by Ault Lending, LLC, respectively. Additional holdings include 11,068 shares held indirectly by Ault Life Sciences, Inc. and 61 shares indirectly by Ault Life Sciences Fund, LLC. The Form 4 is signed by Mr. Ault on 09/30/2025.
Alzamend Neuro, Inc. (ALZN) Schedule 13D/A discloses that Milton C. Ault, III and affiliated entities collectively beneficially own 509,315 shares, equal to approximately 13.3% of the 3,439,861 shares outstanding reported to the reporting persons. Related entities Hyperscale Data, Inc. and Ault Lending, LLC are reported to beneficially own approximately 496,343 shares (13.0%) and 496,331 shares (13.0%), respectively.
The filing states sources of funds (working capital, personal funds) and itemizes aggregate purchase prices for specific holdings and convertible instruments (for example, ~839.24 shares of Series B convertible preferred and related warrants for approximately $839,245). Item 5 notes no transactions in the past 60 days except as set forth in Exhibit 1.
Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in September 2025 affecting both direct and indirect holdings. The filings show open-market dispositions on 09/23/2025 (43,238 shares at $2.3757) and 09/24/2025 (39,140 shares at a $2.3090 VWAP), plus a 09/25/2025 sale of 14,628 shares at $2.3126. On 09/25/2025 Mr. Ault reported conversion of Series B convertible preferred stock into 100,000 common shares at $2.32 per share. The report lists additional holdings indirectly held through related entities (Ault Lending, Ault Life Sciences, and Ault Life Sciences Fund) and warrants and convertible preferred interests held by Ault Lending.
Alzamend Neuro, Inc. reported that between September 17 and September 25, 2025, it issued 300,000 shares of common stock upon the conversion of an aggregate of 696 shares of Series B Convertible Preferred Stock. These common shares were issued in a private transaction relying on an exemption from registration under Section 4(a)(2) of the Securities Act.
After these conversions, Alzamend Neuro had 3,439,861 shares of common stock outstanding as of September 25, 2025, giving investors an updated view of the company’s equity base and recent preferred-to-common share activity.
Alzamend Neuro, Inc. (ALZN) Schedule 13D/A amends prior disclosures to report beneficial ownership positions held by Milton C. Ault, III and affiliated entities. The filing states 3,339,861 shares outstanding and reports that Mr. Ault may be deemed to beneficially own 606,321 shares, or approximately 15.9% of the common stock, through a combination of direct holdings, warrants and shares underlying Series B convertible preferred stock held by affiliated entities.
The filing also reports that Hyperscale Data, Inc. and Ault Lending, LLC may each be deemed to beneficially own approximately 15.5% (593,349 and 593,337 shares respectively). Other reporting persons (Horne, Nisser, Cragun, Katzoff) hold much smaller positions, generally representing shares and options exercisable within 60 days. Item 3 discloses sources of funds and aggregate purchase prices for specified holdings and instruments.
Milton C. Ault III, a director and >10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in September 2025. On 09/19/2025 he disposed of 77,009 common shares at $2.3485, leaving 8,260 shares beneficially owned indirectly through Ault Lending, LLC. On 09/22/2025 he converted Series B convertible preferred stock into 100,000 common shares at a conversion price of $2.32, bringing indirect beneficial ownership through Ault Lending to 108,260 shares. The filing also discloses additional indirect holdings: 11,068 shares held by Ault Life Sciences, Inc. and 61 shares held by Ault Life Sciences Fund, LLC. Derivative holdings include Series B preferred interests and several warrants held indirectly by Ault Lending, LLC.